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In this Phase I/II trial, the patient’s peripheral blood dendritic cells were pulsed with an autologous tumour lysate of the glioma. Seven
patients with glioblastoma and three patients with anaplastic glioma, ranging in age from 20 to 69 years, participated in this study. The
mean numbers of vaccinations of tumour lysate-pulsed dendritic cells were 3.7 times intradermally close to a cervical lymph node, and
3.2 times intratumorally via an Ommaya reservoir. The percentage of CD56-positive cells in the peripheral blood lymphocytes
increased after immunisation. There were two minor responses and four no-change cases evaluated by radiological findings. Dendritic
cell vaccination elicited T-cell-mediated antitumour activity, as evaluated by the ELISPOT assay after vaccination in two of five tested
patients. Three patients showed delayed-type hypersensitivity reactivity to the autologous tumour lysate, two of these had a minor
clinical response, and two had an increased ELISPOT result. Intratumoral CD4þ and CD8þ T-cell infiltration was detected in two
patients who underwent reoperation after vaccination. This study demonstrated the safety and antitumour effects of autologous
tumour lysate-pulsed dendritic cell therapy for patients with malignant glioma.
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Despite advances in radiation and chemotherapy along with
surgical resectioning, the prognosis for patients with malignant
glioma is poor. Among the new treatments currently being
investigated for malignant glioma, immunotherapy is theoretically
very attractive, since it offers the potential for high tumour-specific
cytotoxicity (Dranoff et al, 1993; Sampson et al, 1996; Yu et al,
2001). Previous immunotherapeutic treatments for brain tumours
have focused on passive, adoptive, and nonspecific strategies, and
have failed to yield clear benefits. The central nervous system
(CNS) has been considered to be immunologically privileged based
on the fact that tissue or tumour allografts survive better in the
brain than in extracerebral locations (Medawar, 1948). Glioma cells
are poor antigen-presenting cells (APCs) for the immune system
because of the downregulation in glioma cells of costimulatory
molecules required to activate the immune system (Satoh et al,
1995), and the secretion by glioma cells of immunosuppressive
cytokines such as transforming growth factor-b (TGF-b) (Constam
et al, 1992), vascular endothelial growth factor (VEGF) (Gabrilo-
vich et al, 1999), and interleukin (IL)-10 (Chen et al, 1994).
However, subcutaneous vaccination with genetically modified
cytokine-secreting tumour cells has been demonstrated to be
efficacious against intracranial tumours in a murine model, which
supports the notion that an effective immune response can be
generated against intracerebral tumours (Dranoff et al, 1993;
Sampson et al, 1996). There are an increasing number of reports
(Liau et al, 1999, 2000; Heimberger et al, 2000; Akasaki et al, 2001;
Aoki et al, 2001; Kikuchi et al, 2001; Ni et al, 2001; Yamanaka et al,
2001, 2002; Yu et al, 2001; Insug et al, 2002; Witham et al, 2002)
demonstrating that systemic immunotherapy using dendritic cells
(DCs) is capable of inducing an antitumour response within the
immunologically privileged brain, confirming that the CNS may
not be an absolute barrier to DC-based immunotherapy. Dendritic
cells are rare, haematopoietically derived leucocytes that form a
cellular network involved in immune surveillance, antigen capture,
and antigen presentation (Steinman et al, 1997). With the
availability of techniques for the isolation and bulk propagation
of DCs in vitro, great efforts have been made to use DCs in various
immunisation strategies (Fong and Engleman, 2000). Many
strategies for delivering antigens into DCs have been established
in murine models and are now undergoing evaluation in clinical
trials. These include the use of synthetic peptides where the
tumour antigen is known (Mayordomo et al, 1995), stripped
peptides derived from class I molecules from tumours (Tjoa et al,
1998), tumour RNA (Boczkowski et al, 1996), and tumour lysates
(Heimberger et al, 2000; Aoki et al, 2001; Ni et al, 2001), and fusing
DCs and tumour cells as a vaccine (Gong et al, 1997, 2000). The use
of synthetic peptide approaches requires identification of tumour-
specific antigens for individual tumours and demonstration of
their recognition by cytotoxic T-lymphocytes (CTLs), a process
that is difficult. To date, therefore, there has been limited
identification of the antigenic peptides and CTL epitopes presented
by human gliomas (Yamanaka et al, 2003). The advantages of
vaccinating with total tumour-derived material, such as tumour
cell lysates or tumour-derived mRNA, are that the identities of Received 21 January 2003; revised 10 July 2003; accepted 15 July 2003
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ltumour antigens need not be known and that the use of multiple
tumour antigens reduces the risk of antigen-negative escape
mutants. The administration of DCs therapy has mainly been
through the intradermal or intranodal route. Intratumorally
injected DCs expressing IL-12 migrated to the draining lymph
node and induced therapeutic antitumour immunity (Nishioka
et al, 1999). We have investigated both intradermal and
intratumoral injection of DCs in this study. Here, we describe
the vaccination of 10 malignant glioma cases with DCs pulsed by
an autologous tumour lysate. The safety and immunological
responses of this study are discussed. Systemic cytotoxicity and
intratumoral T-cell infiltration were elicited in some of the
patients.
MATERIALS AND METHODS
Patient population
There were 10 patients enrolled in this Phase I/II study: six women
and four men with an age range from 20 to 69 years (average, 46. 1
years; Table 1). Patients had histologically proven glioblastoma,
anaplastic astrocytoma, or other malignant gliomas according to
the World Health Organization (WHO) criteria. After surgical
resection of their tumour, patients had a course of external beam
radiation therapy (standard dose, 40Gy to the tumour with 3-cm
margins, 20Gy boost to the whole brain). Patients were monitored
for recurrence of their tumour after the initial and maintenance
therapy by magnetic resonance imaging (MRI) or computed
tomography (CT), and had no chemotherapy or radiotherapy
during the previous 4 weeks. The patients started receiving DC
immunotherapy when the recurrence was detected. Treatments
were carried out at the Department of Neurosurgery, Niigata
University Hospital. Five patients (Cases 2, 4, 5, 7, and 9 in Table 1)
had a maintenance dose (predonine, 30mgday
 1) of glucocorti-
coid therapy during the immunotherapy. The median Karnofsky
performance scale was 54, ranging from 30 to 80. Exclusion criteria
included pulmonary, cardiac, or other systemic disease, an acute
infection, and a history of an autoimmune disease.
Generation of dendritic cells from peripheral blood
A concentrated 100ml leucocyte fraction was generated through a
1-h restricted peripheral blood leukapheresis processing 3–4l of
blood with each collection. Peripheral blood mononuclear cells
(PBMCs) were then purified using Ficoll-Hypaque (Sigma, Tokyo)
density gradient centrifugation. Peripheral blood mononuclear
cells were resuspended in RPMI-1640 (Invitrogen, Tokyo) with 1%
autologous heat-inactivated serum, plated at a concentration of
5 10
6cellsml
 1 and allowed to adhere to 10cm
2 dishes.
Nonadherent cells were removed after 4h at 371C in a humidified
5% CO2/95% air incubator, and the adherent cells were cultured at
371C for 7 days in RPMI-1640 medium supplemented with 1%
heat-inactivated autologous serum, in the presence of 1000Uml
 1
recombinant human granulocyte – macrophage colony-stimulating
factor (GM-CSF; Immunex Corp., Seattle, WA, USA), 500Uml
 1
recombinant human IL-4 (R&D Systems, Inc., Minneapolis, MN,
USA), and 1% penicillin/streptomycin (Invitrogen, Tokyo). After 7
days of culture, semiadherent and nonadherent cells were
harvested by pipetting and used as dendritic cells for pulsing with
the tumour lysate as described below. The DCs were stained with
anti-human CD3, CD4, CD8, CD14, CD16, CD19, CD40, CD86,
CD80, CD83, CD56, MHC I, and MHC II monoclonal antibodies
(Pharmingen, San Diego, CA, USA) for 30min at 41C. Species- and
isotype-matched monoclonal antibodies were used as controls.
Preparation of tumour lysate
Tumour tissue was removed from the vivid glioma portion seen in
the microsurgical scope at the operation, and immediately placed
in phosphate-buffered saline (PBS). Adjacent nonglioma tissue was
removed using a scalpel, and tumour cells were dispersed to create
a single-cell suspension. Aliquots were taken for cell counting and
viability staining by trypan blue exclusion. Cells were lysed by
three to five freeze cycles in liquid nitrogen and thaw cycles at
room temperature. Lysis was monitored by light microscopy.
Large particles were removed by centrifugation (15min, 400g),
and the supernatants were passed through a 0.45mm filter. The
protein contents were determined and aliquots were stored at
 801C until use.
DC pulsing
Following 7 days of culture, DCs were further cultured overnight
with 50mgml
 1 keyhole limpet haemocyanin (KLH) (Calbiochem,
Bad Soden, Germany) and the tumour lysate. Approximately
1 10
7 DCs were cultured with 725mg of autologous tumour lysate.
The cells were washed three times with PBS and resuspended in
RPMI-1640 as described below.
Design of the phase I/II trial of DC therapy (Figure 1)
The study protocol was approved by the Ethical Committee of
Niigata University. All patients provided informed consent before
treatment. Patients received the DCs pulsed with the autologous
tumour lysate every 3 weeks for a minimum of one, and a
maximum of 10, immunisations (Table 2). Eligible patients
received four vaccinations at 3 weekly intervals. The immunisation
was subsequently continued for up to 10 vaccinations, depending
on the clinical response. Dendritic cells ranging from 10 10
6 to
32 10
6 cells were injected per vaccination. Dendritic cells were
injected intradermally close to a cervical lymph node and/or
intratumorally via an Ommaya reservoir. Those patients who had a
settled Ommaya reservoir at an appropriate tumour cavity received
an intratumoral DC injection. Patients were monitored for
Table 1 Patient characteristics
Case Age/sex Pathological diagnosis KPS
1 46M Glioblastoma 30
2 40F Glioma 40
3 53F Glioblastoma 80
4 47F Anaplastic mixed glioma 40
5 60M Glioblastoma 30
6 65F Glioblastoma 80
7 69M Glioblastoma 40
8 20F Glioblastoma 80
9 34M Anaplastic oligoastrocytoma 60
10 27F Glioblastoma 70
DC DC DC DC
10w 9w 6w 3w -1w 0
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Figure 1 Flow chart of the phase I/II trial of DC therapy.
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limmediate and delayed toxicities. All toxicity was graded using the
National Cancer Institute Common Toxicity Criteria. The overall
survival time in weeks was estimated from the onset of disease to
death or the present time. The response to the treatment was
evaluated by clinical observations and radiological findings.
Magnetic resonance imaging or CT scanning was performed to
evaluate the intracranial lesions after the vaccinations every
month. Tumour size was estimated as the volume of the region
of abnormal enhancement observed on MRI or CT via direct
measurement. Responses were classified into the following
categories based on Macdonald’s criteria (Macdonald et al,
1990): (a) complete response (CR), defined as disappearance of
the entire tumour for a period of at least 4 weeks; (b) partial
response (PR), defined as a reduction of 50% or more in the
tumour size for at least 4 weeks; (c) minor response (MR), defined
as a 25–50% decrease of lesions lasting at least 4 weeks or a more
than 50% decrease of lesions lasting less than 4 weeks; (d) no
change (NC), defined as either a decrease of less than 25% or an
increase of less than 25% in tumour size for at least 4 weeks; (e)
progressive disease (PD), defined as an increase of 25% or more in
tumour size. The end points of this study were evaluations of the
toxicity, immunological response, and clinical response after DC
therapy.
Delayed-type hypersensitivity (DTH) reaction
To test the cell-mediated cytotoxicity response, 0.05mg purified
tuberculin and 10mg autologous tumour lysate were administered
intradermally into the forearm before and after treatment. A
positive DTH skin-test reaction was defined as 42mm diameter
induration after 48h.
IFN-c ELISPOT assay
Wells of MultiScreen-HA plates (Millipore, Bedford, MA, USA)
were coated with 100ml of a mouse anti-human IFN-g antibody
(2mgml
 1, clone 1-D1K; Mabtech, Nacka, Sweden) in PBS. After
incubation overnight at 41C, unbound antibody was removed by
six washes with PBS. Coated wells were blocked with 100ml RPMI-
1640 supplemented with 1% bovine serum albumin (BSA; Sigma).
After 2h at 371C, the blocking medium was discarded. Mono-
nuclear cells (2 10
5well
 1 were used as stimulator cells and
plated in each well. Tumour lysate-pulsed DCs (1 10
4well
 1 were
admixed to each well. After a 6-h incubation at 371C, cells were
removed by six washes with PBS plus 0.05% Tween 20 (PBST), and
100ml of a biotinylated detection antibody against human IFN-g
(0.75mg/ml
 1, clone 7-B6-1; Mabtech) was added per well. After
20h at 371C, plates were rinsed six times with PBST. Then, 100ml
of a streptavidin-alkaline phosphatase complex preparation
(Mabtech) was added to each well at a dilution of 1:1000 and
incubated for 1h at room temperature. Unbound complexes were
removed by three washes with PBST and three washes with PBS.
The staining reaction was initiated by adding a solution of 5-
bromo-4-chloro-3-indolyl-phosphate (BCIP)/nitroblue tetrazolium
(NBT) (BIO-RAD Lab., Hercules, CA, USA) dissolved according to
the manufacturer’s instructions. The reaction was stopped after
5min by washing the plates under running tap water. Spots were
counted using a stereomicroscope (Zeiss, Jena, Germany) at  40
magnification. The cutoff for positive spots was defined as a spot
size greater than 3 s.d. above the mean value of the spot diameter
obtained in the absence of the DCs.
Cell surface analysis
Peripheral blood mononuclear cells were separated from the
peripheral blood of patients, resuspended in PBS containing 1%
BSA and 0.1% sodium azide (Sigma), and stained with anti-human
CD3, CD4, CD8, CD14, CD16, CD19, CD40, CD86, CD80, CD83,
CD56, MHC I, and MHC II monoclonal antibodies (Pharmingen,
San Diego, CA, USA) for 30min at 41C. Stained cells were washed
and analysed using FACScan (Becton Dickinson, San Jose, CA,
USA).
Immunohistochemistry
Serial 10mm paraffin sections of the surgical intracranial tumour
specimen were stained with mouse anti-human monoclonal
antibodies against CD3, CD4, CD8, CD20, and CD56 (1:50
dilutions; Pharmingen). Primary antibodies were detected with
an FITC-conjugated goat anti-mouse IgG secondary antibody
(1:500 dilution; Pharmingen). Sections were examined in a Zeiss
Axiophot 2 fluorescence microscope (Zeiss).
Statistical analysis
The pre- and postvaccination data were compared using Wilcox-
on’s test. Statistical significance was determined at the o0.05 level.
RESULTS
Isolation and characterisation of DCs
Mononuclear cells (0.35–9 10
8; average, 4.9 10
8) were isolated
by Ficoll-Hypaque density gradient centrifugation and differen-
tiated into DCs in the presence of GM-CSF and IL-4. The final yield
of DCs after 7 days of culture was 0.3–4 10
8 (average, 1.36 10
8).
Dendritic cells of the immature phenotype (CD3neg, CD14neg,
CD16neg/CD56neg, CD19neg, MHC I pos, MHC II pos, CD40low,
CD86low, and CD83low) were greater than 75% (data not shown).
These DCs were divided into six tubes, and cryopreserved in 90%
RPMI-1640 supplemented with 10% autoplasmaþ10% DMSO in
liquid nitrogen. One cryopreserved vial was thawed and used for
each vaccination. The DCs were tested for endotoxin and
mycoplasma prior to administration to the patient.
Table 2 Results of dendritic-cell (DC) immunotherapy
Case No. of vaccination Total amount of DCs ( 10
6) Radiological findings Adverse effects Overall survival (weeks) Outcome
1 2(id) 10(id) NC No 73 Dead
2 2(id), 2(it) 17(id), 17(it) NC No 216 Dead
3 4(id), 4(it) 42.4(id),52.4(it) MR No 100 Dead
4 1(id), 1(it) 12.6(id),12.6(it) NC No 188 Dead
5 2(id), 2(it) 64(id), 64(it) PD No 63 Dead
6 10(id), 7(it) 137.2(id),106.6(it) MR Grade 1 308+ SD
7 3(id) 46(id) PD No 52 Dead
8 6(id) 37.5(id) NC No 60 Dead
9 4(id) 28.2(id) PD No 98 Dead
10 3(id) 20.6(id) PD No 564+ PD
SD¼stable disease; PR¼partial response; MR¼minor response; NC¼no change; PD¼progressive disease; id¼intradermal vaccination; it¼intratumoral vaccination.
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Intradermal and/or intratumoral vaccination with DCs was
performed. The mean numbers of administrations were 3.7 times
intradermally, and 3.2 times intratumorally, ranging from 1 to 10.
The mean total numbers of inoculated DCs were 4.155 10
7 cells
for intradermal injection, and 5.052 10
7 cells for intratumoral
injection (Table 2). There were no serious adverse effects, clinical
or radiological evidence of autoimmune reaction, in any of the
patients (Table 2). There were no substantial changes in the results
of routine blood tests (data not shown). Patient 6 developed a mild
headache lasting a few days after vaccination. In two cases (Cases 4
and 6), mild erythema at the cervical injection site manifested after
the third immunisation, suggesting that DTH had occurred.
Delayed-type hypersensitivity reactivity
Delayed-type hypersensitivity, using purified tuberculin or the
autologous tumour lysate, was performed before and after
treatment. Three of five patients showed reactivity to the purified
tuberculin before and after vaccination. Three of six patients
showed reactivity to the autologous tumour lysate; two of these
had a minor reaction on MRI or CT, and two had an increased
ELISPOT result after vaccination. Two of three patients who
showed reactivity to the autologous tumour lysate also exhibited
reactivity to purified tuberculin.
Clinical responses
The clinical response data are listed in Table 2. There were two
minor responses (Cases 3 and 6). In Case 3, although the size of the
low density area did not decrease, the contrast enhanced lesion was
decreased (Figure 2A, B). Case 6 had convulsions that worsened at
the beginning of immunisation. The patient showed a slight
improvement in the convulsions after the immunisations, and MRI
showed a reduction in the size of enhanced lesions of the tumour
(Figure 2C, D). There were four no-change cases on MRI.
CD56-positive cells in PBL increased after vaccination
The surface phenotype of the peripheral blood lymphocytes was
investigated using FACScan before and after immunotherapy. We
analysed the expressions of CD3, CD4, CD8, CD16, CD19, and
CD56 in five of 10 cases. No constant changes in the percentages of
CD3 or CD4 were detected in the periods before and after therapy,
whereas the percentages of CD8-, CD16-, and CD19-positive cells
slightly increased in four of five cases; CD56-positive cells slightly
increased in all cases analysed (Table 3). There was a significant
increase in CD56-positive cells in PBL after vaccination (Po0.05).
Detection of tumour lysate-reactive CD8þ T cells in the
blood of glioma patients
By ELISPOT analysis, blood samples of five glioma patients were
tested for the presence of tumour lysate-reactive CD8þ T cells in
PBMC from patients’ prevaccination, and 1 week after the last
vaccination. To determine the frequency of tumour lysate-reactive
CD8þ T cells by the IFN-g ELISPOT assay, monocytes were
prepared from the blood of the five glioma patients, loaded with
tumour lysate-pulsed DCs, and then cocultured. As a negative
control, PBMCs were not pulsed with DCs. The results of the
ELISPOT analysis are summarised in Figure 3. T cells reactive
against tumour lysate-pulsed DCs were increased in two patients
after vaccination (Po0.05). On the other hand, only weak T-cell
responses against tumour lysate-pulsed DCs were observed in
three glioma patients after vaccination.
Figure 2 Computed tomography of Case 3 shows that, although the
size of the low density area did not change, the contrast enhanced lesion
was decreased. Computed tomography contrast enhanced images before
(A) and after (B) vaccination. Magnetic resonance imaging of Case 6 shows
that the contrast enhanced lesion was decreased after vaccination. Contrast
enhanced MRI before (C) and after (D) vaccination.
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lIntracranial infiltration of T cells after vaccination
Two patients (Cases 8 and 10 ) who developed tumour progression,
as suggested by new areas of contrast enhancement on MRI or CT,
underwent reoperation subsequent to the third intradermal
vaccination. These patients developed CD4þ and CD8þ T-cell
infiltration in areas of the tumour that were not apparent in the
tumour specimen obtained before vaccination (Figure 4). There
were no CD20þ B cells detectable before or after vaccination (data
not shown). There were no increases in the number of
intratumoral lymphocytes in specimens from five nonvaccinated
glioblastoma patients who underwent reoperation (data not
shown). Thus, enhanced CD4þ and CD8þ T-cell infiltration
seems to be a characteristic of the subset of vaccinated patients
who underwent reoperation.
Intradermal vs intratumoral and intradermal
administration comparisons
As shown in Table 4, five patients (Cases 1, 7, 8, 9, and 10) had
intradermal administration, and five other patients (Cases 2, 3, 4,
5, and 6) had both intradermal and intratumoral administration.
In the intradermal administration group, DTH reaction to the
tumour lysate was positive in one of three tested cases, ELISPOT
assay was positive in one of three tested cases, and there were two
NCs and three PDs radiological findings after vaccination. In the
intradermal plus intratumoral administration group, DTH reaction
to the tumour lysate was positive in two of three tested cases,
ELISPOT assay was positive in one of two tested cases, and there
were two MRs, two NCs and one PD radiological findings after
vaccination. A clinical response was observed in the intradermal
plus intratumoral administration group.
DISCUSSION
Dendritic-cell-based therapy is currently being evaluated in clinical
trials for a variety of tumours. The initial results obtained from
clinical trials of DC-based therapy for B-cell lymphoma (Hsu et al,
1996), melanoma (Nestle et al, 1998), prostate cancer (Tjoa
et al, 1998), and renal cell carcinoma (Kugler et al, 2000) have
recently been published, and the results appear to be encouraging.
Antigen-specific immunity has been shown to be induced in the
majority of patients during DC vaccination, and regression of
metastases was observed in 30% of patients (Nestle et al, 1998).
The remarkable ability of DCs to elicit immune responses and the
availability of DC culture systems has allowed the use of DCs in
cancer immunotherapy. Large numbers of functional DCs can be
isolated from bone marrow precursor cells treated in vitro with
cytokines such as GM-CSF, IL-4, and tumour necrosis factor
(TNF)-a. Together, these findings demonstrate that autologous
DCs from tumour-bearing hosts can be expanded ex vivo, pulsed
with tumour antigens, and reintroduced to induce tumour-specific
T cells. In murine models and in clinical trials, these cytokine-
stimulated DCs have been successfully pulsed ex vivo with tumour
antigens for use as antitumour vaccines against several types of
malignancies.
In this Phase I/II trial, the patient’s peripheral blood DCs were
pulsed with the autologous tumour lysate of the glioma. The mean
numbers of vaccinations were 3.7 times intradermally close to a
cervical lymph node, and 3.2 times intratumorally via the Ommaya
reservoir. There were two minor responses and four no-change
cases, as evaluated by radiological findings. Dendritic cell
vaccination elicited T-cell-mediated antitumour activity, as eval-
uated by the ELISPOT assay, after vaccination in two of five tested
patients. These two patients who demonstrated CTL activity in the
Table 3 Surface phenotypes of PBLs pre- and postvaccination with dendritic cells
CD3(%) CD4(%) CD8(%) CD16(%) CD19(%) CD56(%)
Case Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
3 70.38 63.32 37.52 27.16 30.02 37.52 6.4 7.92 20.26 23.46 19.34 23.2
5 41.34 41.96 30.9 31.28 24.84 43.6 41.24 33.82 11.32 17 47.42 53.06
6 66 66.56 36.3 29.8 39.8 48.14 17.5 19.92 5.5 3.34 28.1 28.36
7 69.14 64.28 35.14 28.22 47.64 47.14 15.88 17.52 11.98 15.5 20.14 23.64
8 78.68 71.78 45.16 40.48 35.26 43.04 2.9 15.28 6.44 24.44 15.36 22.18
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Figure 3 T-cell-mediated antitumour activity of PBMCs of glioma
patients, as evaluated by the ELISPOT assay before and after vaccination.
Data are shown as the median values7standard deviation (n¼3).
Statistical significance was assessed by Student’s t-test. *Po0.05.
Table 4 Intradermal vs intratumoral and intradermal administration
comparisons
Case
DTH reaction to
tumour lysate
ELISPOT
assay
Radiological
findings
Intradermal administration
1   ND NC
7N D   PD
8+ + N C
9N D   PD
10   ND PD
Intratumoral and Intradermal
administration
2N D N D N C
3+   MR
4N D N D N C
5   ND PD
6+ + M R
+¼positive;  ¼negative; ND¼not tested; MR¼minor response; NC¼no
change; PD¼progressive disease.
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There was a significant increase in CD56-positive cells in PBL after
vaccination, suggesting that DC therapy activated systemic NK
cells. Intratumoral CD4þ and CD8þ T-cell infiltration was
detected in two patients who underwent reoperation after
vaccination. These patients who underwent reoperation demon-
strated MR or NC response, as evaluated by MRI. Case 3 and Case
6 patients, who received intradermal and intratumoral injections,
both had a positive DTH reaction and a minor clinical response.
Intratumorally injected DCs may induce more efficient antitumour
immunoresponses. This study demonstrated the safety, antitu-
mour immunoresponses, and clinical response of autologous
tumour lysate-pulsed DC therapy for patients with malignant
glioma. Furthermore, in our in vitro study, DCs pulsed with a
normal brain lysate failed to induce cytolytic T-cell activity against
autologous glioma cells, suggesting the lack of an autoimmune
response (data not shown). There were also no serious adverse
effects, or clinical or radiological evidence of autoimmune
reaction, in any of the patients in this study. Although there is
some probability of shared antigens between tumour and normal
CNS tissue, and possible contamination of normal tissue in the
tumour lysate, we have not observed autoimmunity either in vitro
or in vivo.
Intratumorally injected DCs would acquire and process tumour
antigens in situ, migrate to regional lymphoid organs via lymphoid
vessels, and initiate a significant tumour-specific immune
response. It has been reported that DCs have antigen-capturing
and processing as well as trafficking abilities only during their
immature phase (Inaba et al, 1993). We generated immature phase
DCs by GM-CSF and IL-4, without TNF-a. In all cases, the DC
preparation was loaded with KLH protein, since KLH has been
shown to serve as a strong surrogate antigen and an immunogenic
marker for immunisation studies using DC-based vaccines (Hsu
et al, 1996; Nestle et al, 1998).
There have been several reports (Liau et al, 1999; Heimberger
et al, 2000; Akasaki et al, 2001; Aoki et al, 2001; Ni et al, 2001;
Yamanaka et al, 2001, 2002; Insug et al, 2002; Witham et al, 2002)
on murine glioma models for DC-based therapy. These animal
studies of DC therapy for glioma differ from each other. These
differences are the source of the DCs, type of antigen, adminis-
tration route, dose, and number of vaccinations. The antigens used
varied, and included tumour lysate admixed with liposomes,
whole-tumour mRNA, whole-tumour peptides, virus vector-
mediated tumour cDNA, glioma apoptotic bodies, and fusions of
DCs and tumour cells. Most investigators used bone marrow DCs
as the source of DCs, except for one cloned DC line. The
administration route was intraperitoneal, except for one case of
subcutaneous administration. They reported that DC therapy led
to prolonged survival in rodents with established tumours, and
also induced specific cytotoxic activity. No severe autoimmune
responses occurred in any of the studies using animal models.
Therefore, DC-based systems are expected to serve as powerful
tools for treating patients with malignant glioma.
There have been two reports (Kikuchi et al, 2001; Yu et al, 2001)
of DC-based clinical trials of vaccination of glioma patients. The
source of the DCs in these cases were PBMCs cultured with GM-
CSF, IL-4, and TNF-a. Dendritic cells were stimulated with tumour
antigens using peptides eluted from autotumour cells, or fusions of
DCs and autotumour cells. The administration route was
intradermal injection close to a cervical lymph node such as the
Figure 4 Immunohistochemical characterisation of infiltrating cells in an
intracranial tumour at first surgery, before vaccination and at reoperation
after vaccination. (A) CD4þ T cell before vaccination; (B) CD4þ T cell
after vaccination; (C) CD8þ T cell before vaccination; (D) CD8þ T-cell
after vaccination (magnification  400).
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immunological response, tumour size as determined by MRI or
CT, and survival.
Yu et al (2001) reported a phase I trial of peripheral blood DCs
pulsed with peptides eluted from the surface of autologous glioma
cells. Five women and four men were enrolled in this study. Two
patients had anaplastic astrocytoma and seven had glioblastoma.
Prior to DC treatment, patients had undergone surgical resection
of the tumours followed by irradiation therapy. A total of 1 million
peptide-pulsed DCs were injected intradermally in the deltoid
region three times biweekly. Dendritic-cell vaccination elicited
systemic cytotoxicity in four of seven patients, and intratumoral
cytotoxic and memory T-cell infiltration was detected in two of
four patients who underwent reoperation after vaccination. No
significant adverse effects were seen. They also reported increased
survival: the median survival times for the study and control
groups were 455 and 257 days, respectively.
Kikuchi et al (2001) reported immunotherapy with fusion of
DCs and glioma cells. Eight patients with malignant glioma
participated in this study. Dendritic cells were generated from
peripheral blood, and cultured autologous glioma cells were
established from surgical specimens in each case. Fusion cells
produced using dendritic and glioma cells were prepared with
polyethylene glycol with an average fusion efficiency of 21.9%.
Patients received the fusion cells every 3 weeks intradermally close
to a cervical lymph node. The number of fusion cells injected
ranged from 2.4 10
6 to 8.7 10
6 cells per vaccination. The
percentage of CD16þ/CD56þ cells and the production of IFN-g
in peripheral blood lymphocytes increased after immunisation.
Clinically, there were no serious adverse effects and two partial
responses. Magnetic resonance imaging of two cases showed that,
in the first case, the size of the primary tumour was decreased
although there was progression of the secondary lesion after
immunisation. In the second case, although the size of the tumour
itself had not changed, a reduction of the brain oedema was
observed.
Dendritic-cell vaccination of patients with glioma appears to be
safe and not associated with autoimmunity. Toxicities included
mild headache in one patient in our study. The only adverse effects
reported were mild fever and swelling of an injected lymph node
(Nestle et al, 1998), and no other significant adverse effects have
been reported in DC therapy clinical trials, or in animal models of
DC therapy. Due to the limited populations studied thus far,
further evaluation of DC immunotherapy is necessary in order to
determine the optimum dose of DCs, the appropriate route of
vaccinations, the best source of tumour antigens, and methods of
antigen loading.
Phase II studies of DC-based glioma therapy are underway to
confirm its effects on survival in patients with malignant glioma.
The DC-based immunotherapy strategy appears promising as an
approach for inducing antitumour immune responses and a
clinical response in patients with glioma. The efficacy of such
protocols should be determined in randomized, controlled clinical
trials. The development of methods for manipulating the vaccina-
tion of DCs will enhance the clinical usefulness of DC-based
biotherapy for malignant glioma.
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